Literature DB >> 29636994

Targeting autophagy in chemotherapy-resistant of hepatocellular carcinoma.

Jiyao Sheng1, Hanjiao Qin2, Kun Zhang3, Bingjin Li3, Xuewen Zhang1.   

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor with poor prognosis. Surgical resection is recommended for very early-stage and early-stage HCC, but HCC is still prone to recurrence and metastasis after surgery. Furthermore, treatment options for intermediate- and advanced-stage HCC are relatively limited. Systemic therapy is the preferred method to kill residual cancer cells after surgery and prolong survival time of inoperable patients, but most cases are insensitive to chemotherapeutic agents, restricting widespread clinical application of systemic therapy. Many studies have found that various chemotherapeutic drugs for HCC treatment can increase autophagic flux of HCC cells, and it may be related with enhancing drug resistance and promoting cell survival. However, enhancement of autophagic flux may also induce tumor cell death in some cases, leading to marked inconsistency across studies. Here we reviewed the mechanisms underlying the increase in autophagic flux in HCC cells induced by chemotherapeutic drugs and examined the contributions of autophagy and related pathways to chemotherapy drug resistance. Our aim was to identify potential autophagy-related targets for improving the sensitivity of HCC to chemotherapeutic drugs.

Entities:  

Keywords:  Hepatocellular carcinom; autophagy; cancer; chemotherapy-resistant

Year:  2018        PMID: 29636994      PMCID: PMC5883089     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  89 in total

Review 1.  Cell death by autophagy: facts and apparent artefacts.

Authors:  D Denton; S Nicolson; S Kumar
Journal:  Cell Death Differ       Date:  2011-11-04       Impact factor: 15.828

Review 2.  Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis.

Authors:  John J Lemasters
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Verslype; O Rosmorduc; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

Review 4.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

5.  Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion.

Authors:  Jing Zhou; Shi-Hao Tan; Valérie Nicolas; Chantal Bauvy; Nai-Di Yang; Jianbin Zhang; Yuan Xue; Patrice Codogno; Han-Ming Shen
Journal:  Cell Res       Date:  2013-01-22       Impact factor: 25.617

6.  Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62.

Authors:  J-P Pursiheimo; K Rantanen; P T Heikkinen; T Johansen; P M Jaakkola
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

Review 7.  The role of autophagy in hepatocellular carcinoma: friend or foe.

Authors:  Lian Liu; Jia-Zhi Liao; Xing-Xing He; Pei-Yuan Li
Journal:  Oncotarget       Date:  2017-04-18

8.  MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.

Authors:  Fangfang Jin; Yanbo Wang; Mingzhen Li; Yanan Zhu; Hongwei Liang; Chen Wang; Feng Wang; Chen-Yu Zhang; Ke Zen; Limin Li
Journal:  Cell Death Dis       Date:  2017-01-12       Impact factor: 8.469

9.  The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.

Authors:  Carolina Simioni; Alberto M Martelli; Alice Cani; Rengul Cetin-Atalay; James A McCubrey; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2013-09

10.  Autophagy inhibits chemotherapy-induced apoptosis through downregulating Bad and Bim in hepatocellular carcinoma cells.

Authors:  Yan Zhou; Kai Sun; Yi Ma; Haozheng Yang; Yuanliang Zhang; Xianming Kong; Lixin Wei
Journal:  Sci Rep       Date:  2014-06-20       Impact factor: 4.379

View more
  20 in total

Review 1.  Interplay of autophagy and cancer stem cells in hepatocellular carcinoma.

Authors:  Magdelyn Mei-Theng Wong; Hui-Yin Chan; Norazlin Abdul Aziz; Thamil Selvee Ramasamy; Jan-Jin Bong; Ewe Seng Ch'ng; Subasri Armon; Suat-Cheng Peh; Sin-Yeang Teow
Journal:  Mol Biol Rep       Date:  2021-04-24       Impact factor: 2.316

2.  Effect of Hematocrit Injury on the Survival Rate of Advanced Malignant Tumors and Its Clinical Significance.

Authors:  Lin Li; Weibin Wu; Mingdi Yin
Journal:  Comput Math Methods Med       Date:  2022-06-15       Impact factor: 2.809

3.  Potentiation of TRAIL‑induced cell death by nonsteroidal anti‑inflammatory drug in human hepatocellular carcinoma cells through the ER stress‑dependent autophagy pathway.

Authors:  Su-Hoon Lee; Hyun-Jung Moon; Young-Shin Lee; Chi-Dug Kang; Sun-Hee Kim
Journal:  Oncol Rep       Date:  2020-06-25       Impact factor: 3.906

Review 4.  Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma.

Authors:  Fang Huang; Bing-Rong Wang; Yi-Gang Wang
Journal:  World J Gastroenterol       Date:  2018-11-07       Impact factor: 5.742

Review 5.  Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases.

Authors:  Hsiang-Cheng Chi; Chung-Ying Tsai; Ming-Ming Tsai; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  J Biomed Sci       Date:  2019-03-08       Impact factor: 8.410

Review 6.  Autophagy: Dual Response in the Development of Hepatocellular Carcinoma.

Authors:  Hamza O Yazdani; Hai Huang; Allan Tsung
Journal:  Cells       Date:  2019-01-28       Impact factor: 6.600

7.  Tenacissoside H Induces Autophagy and Radiosensitivity of Hepatocellular Carcinoma Cells by PI3K/Akt/mTOR Signaling Pathway.

Authors:  Jiatian Lin; Jiyin Ruan; Hao Zhu; Zaizhong Chen; Junhui Chen; Hongjian Yu
Journal:  Dose Response       Date:  2021-05-13       Impact factor: 2.658

8.  Silencing of ATG4D suppressed proliferation and enhanced cisplatin-induced apoptosis in hepatocellular carcinoma through Akt/Caspase-3 pathway.

Authors:  Jing-Yuan Zhao; Xiao-Yun Li; Tian-De Liu; Bo Liang; Yong Huang; Wen Li
Journal:  Mol Cell Biochem       Date:  2021-07-27       Impact factor: 3.396

9.  Dysregulated FAM215A Stimulates LAMP2 Expression to Confer Drug-Resistant and Malignant in Human Liver Cancer.

Authors:  Po-Shuan Huang; Yang-Hsiang Lin; Hsiang-Cheng Chi; Yi-Hsin Tseng; Cheng Yi Chen; Tzu-Kang Lin; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Cells       Date:  2020-04-14       Impact factor: 6.600

10.  Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma.

Authors:  Cheng Zhang; Ning Wang; Hor-Yue Tan; Wei Guo; Feiyu Chen; Zhangfeng Zhong; Kwan Man; Sai Wah Tsao; Lixing Lao; Yibin Feng
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.